EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Utility of Nuchal Translucency Measurement in First‐Trimester Ultrasound Screening in a Setting With First‐Tier NIPT for Aneuploidy Screening

Eline E R Lust iD, Kim Bronsgeest, Lidewij Henneman iD, Neeltje M T H Crombag iD, Caterina M Bilardo, Robert-Jan H Galjaard, Esther Sikkel, Audrey B C Coumans, Ayten Elvan-Taşpınar, Sander Galjaard, Attie T J I Go, Gwendolyn T R Manten und 4 weitere

Prenatal Diagnosis · 07.12.2025

DOI: 10.1002/pd.70047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Prenatal Diagnosis, online erschienen am 07.12.2025. Verfasst von Eline E R Lust und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University Medical Center Utrecht, Utrecht, the Netherlands. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the additional clinical value of nuchal translucency (NT) measurement at the first‐trimester anomaly scan (FTAS) in a setting with first‐tier non‐invasive prenatal testing (NIPT).

Method

This nationwide prospective cohort study, part of the IMITAS study on FTAS implementation, included all pregnancies with increased NT (≥ 3.5 mm) at FTAS, subsequently referred for detailed diagnostic scans at eight Dutch tertiary centers (Nov 2021–Nov 2022). Women with abnormal dating scans, abnormal NIPT before FTAS, or high‐risk for fetal anomalies were not eligible for FTAS and received diagnostic ultrasound directly. The primary outcome was prenatal diagnosis of structural or genetic anomalies based on pre‐ and postnatal findings.

Results

FTAS was performed in 129,704 pregnancies, of which 230 (0.18%) had an increased NT. Anomalies were detected in 33.9% of these cases. Genetic anomalies included 76.8% aneuploidies, 14.3% SNVs, 8.9% CNVs; 39.3% beyond NIPT's detection scope. Trisomy 21/18 was diagnosed in 29.3% referred for increased NT without prior NIPT; 73.5% of these opted for termination. Anomaly prevalence increased with greater NT thickness.

Conclusion

NT measurement adds value in a national screening program including FTAS and NIPT. Prenatal counseling should address trisomies and other genetic abnormalities as a potential result of an abnormal FTAS, particularly when NIPT is declined.

Schlagwörter

Stichwörter der Autor:innen

aneuploidychromosome disorderscongenital abnormalitiesearly diagnosisfetal screeningnoninvasive prenatal testingnuchal translucency measurementprenatal ultrasonography

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Human Genetics and Amsterdam Reproduction and Development Research Institute, Location Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Department of Obstetrics and Gynecology, Amsterdam UMC, Amsterdam, the Netherlands.
  • Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.

ORCID-Profile: Eline E R Lust, Lidewij Henneman, Neeltje M T H Crombag, Elisabeth van Leeuwen, Monique C Haak, Mireille N Bekker

Förderung

  • ZonMw

Zitieren

APA

Lust, E. E. R., Bronsgeest, K., Henneman, L., Crombag, N. M. T. H., Bilardo, C. M., Galjaard, R. H., Sikkel, E., Coumans, A. B. C., Elvan-Taşpınar, A., Galjaard, S., Go, A. T. J. I., Manten, G. T. R., Pajkrt, E., van Leeuwen, E., Haak, M. C., & Bekker, M. N. (2025). Clinical Utility of Nuchal Translucency Measurement in First‐Trimester Ultrasound Screening in a Setting With First‐Tier NIPT for Aneuploidy Screening. Prenatal Diagnosis. https://doi.org/10.1002/pd.70047

Vancouver

Lust EER, Bronsgeest K, Henneman L, Crombag NMTH, Bilardo CM, Galjaard RH, et al. Clinical Utility of Nuchal Translucency Measurement in First‐Trimester Ultrasound Screening in a Setting With First‐Tier NIPT for Aneuploidy Screening. Prenatal Diagnosis. 2025. doi:10.1002/pd.70047

BibTeX
@article{Lust2025,
  author = {Lust, Eline E R and Bronsgeest, Kim and Henneman, Lidewij and Crombag, Neeltje M T H and Bilardo, Caterina M and Galjaard, Robert-Jan H and Sikkel, Esther and Coumans, Audrey B C and Elvan-Taşpınar, Ayten and Galjaard, Sander and Go, Attie T J I and Manten, Gwendolyn T R and Pajkrt, Eva and van Leeuwen, Elisabeth and Haak, Monique C and Bekker, Mireille N},
  title = {Clinical Utility of Nuchal Translucency Measurement in First‐Trimester Ultrasound Screening in a Setting With First‐Tier NIPT for Aneuploidy Screening},
  journal = {Prenatal Diagnosis},
  year = {2025},
  doi = {10.1002/pd.70047}
}
Kostenlos starten →